痛泻方减轻肠易激综合征症状
在中国5家医院纳入1044例符合Rome III标准的成人肠易激综合征患者,随机分为痛泻方组、安慰剂组或匹维溴铵组,每日3次治疗4周。痛泻方在全部6项症状上较安慰剂显著改善,在粪便成形和大便次数上优于匹维溴铵,但匹维溴铵在疼痛及疼痛频率上优于痛泻方。
要点
- 痛泻方治疗4周后全部6项症状较安慰剂显著改善(P < .001)。
- 痛泻方组粪便成形改善比例75.6%,高于匹维溴铵组的50.6%。
- 痛泻方组大便次数减少比例72.7%,高于匹维溴铵组的58.3%。
核心结论
- 为期4周的痛泻方治疗对肠易激综合征症状的改善显著优于安慰剂,在粪便成形和大便次数上优于匹维溴铵。
- 作者认为痛泻方可作为对常规治疗反应不佳的肠易激综合征患者的有效替代疗法。
研究设计与样本
- 随机对照试验,2012年8月至2015年1月在中国5家医院纳入1044例符合Rome III标准的成人肠易激综合征患者。
- 受试者按1:1:1随机分为痛泻方组、安慰剂组或匹维溴铵组,每日3次治疗4周。
- 主要终点为痛泻方组与安慰剂组或匹维溴铵组相比腹痛和Bristol粪便评分的降低幅度;次要终点为疼痛、大便频率、腹部不适及其频率的降低。
主要发现
- 痛泻方组全部6项评估症状在研究前后均显著降低,优于安慰剂组(P < .001)。
- 痛泻方组粪便成形改善比例75.6%,高于匹维溴铵组的50.6%(P < .001)。
- 痛泻方组大便次数减少比例72.7%,高于匹维溴铵组的58.3%(P < .001)。
- 匹维溴铵组疼痛减轻比例63.5%、疼痛频率降低比例69.5%,分别高于痛泻方组的51.4%和58.6%(P < .005)。
关键数值与推荐
- 痛泻方由白术(A macrocephalae)、白芍(P lactiflora)、陈皮(C reticulata)、防风(S divaricata)、党参(C pilosula)、温郁金(C wenyujin)、甘草(C medica)、茯苓(P cocos)等药物根据患者特征组成。
- 匹维溴铵为50 mg片剂,每日3次,治疗4周。
临床怎么用
- 作者认为痛泻方可作为对常规治疗反应不佳的肠易激综合征患者的有效替代疗法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is the most common chronic gastrointestinal disorder, yet few drugs are effective in reducing symptoms. Approximately 50% of patients with IBS attempt herbal therapy at least once. We performed a randomized controlled trial to compare the efficacy of the herb formulation tongxie vs placebo or pinaverium (an antispasmodic agent) in reducing symptoms of IBS. METHODS: We performed a trial of 1044 adult patients with IBS (based on Rome III criteria) at 5 hospitals in China, from August 2012 through January 2015. Subjects were randomly assigned (1:1:1) to groups given tongxie (a combination of A macrocephalae, P lactiflora, C reticulata, S divaricata, C pilosula, C wenyujin, C medica, and P cocos, along with other herbs, based on patient features), placebo, or pinaverium (50 mg tablets) 3 times daily for 4 weeks. Primary end points were significantly greater reductions in abdominal pain and Bristol stool score (before vs after the 4-week study period) in patients given tongxie compared with patients given placebo or pinaverium. Secondary end points were reductions in pain and stool frequencies and abdominal discomfort and its frequency. RESULTS: Subjects given tongxie had significant reductions, before vs after the study period, in all 6 symptoms assessed, compared to patients given placebo (P < .001). A significantly higher proportion of patients given tongxie had increased stool consistency (75.6%) than patients given pinaverium (50.6%), and a significantly higher proportion of patients given tongxie had fewer daily stools (72.7%) than subjects given pinaverium (58.3%) (P < .001 for both). However, significantly higher proportions of patients given pinaverium had reduced pain (63.5%) and pain frequency (69.5%) than patients given tongxie (51.4% and 58.6%, respectively; P < .005 for both). CONCLUSIONS: In a randomized controlled trial of patients with IBS in China, we found 4 weeks of tongxie to produce significantly greater reduction in symptoms than placebo, and greater increases in stool consistency and reductions in stool frequency, than patients given pinaverium. Tongxie can therefore be considered an effective alternative therapy for patients with IBS who do not respond well to conventional therapies. Clinicaltrials.gov no: NCT01641224.
引用
- Fan H, Zheng L, Lai Y, et al. Tongxie Formula Reduces Symptoms of Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2017. PMID: 28634136. doi:10.1016/j.cgh.2017.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。